What is Cerapedics?
Cerapedics is a specialized medical technology firm dedicated to the advancement of bone repair and regeneration. The company is best known for its innovative P-15 Osteogenic Cell Binding Peptide technology, which serves as the foundation for its flagship products, PearlMatrix and i-FACTOR. These bone graft substitutes are engineered to accelerate healing processes in spine, trauma, and orthopedic surgical procedures.
By providing healthcare professionals with evidence-based, high-performance alternatives to traditional bone grafting methods, Cerapedics occupies a critical niche in the orthopedic market. The company's focus on clinical efficacy and patient-centric outcomes positions it as a key innovator in the musculoskeletal health space, consistently driving improvements in surgical standards and recovery times for patients globally.
How much funding has Cerapedics raised?
Cerapedics has raised a total of $128.8M across 9 funding rounds:
Series B
$15M
Series C
$19M
Debt
$9M
Private Equity
$4M
Series A
$16.5M
Series D
$11M
Debt
$20M
Private Equity
$22M
Series B (2009): $15M led by NGN Capital and OrbiMed
Series C (2012): $19M supported by Central Valley Fund, OrbiMed, NGN Capital, and MedImmune Ventures, Inc.
Debt (2014): $9M featuring Healthcare Financial Services, LLC and GE Capital
Private Equity (2015): $4M backed by GE Capital and Healthcare Financial Services, LLC
Series A (2015): $16.5M, investors not publicly disclosed
Series D (2016): $11M, investors not publicly disclosed
Debt (2017): $20M supported by Oxford Finance
Private Equity (2018): $22M featuring KCK Group
Key Investors in Cerapedics
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics to support innovation at various development stages.
NGN Capital
NGN Capital LLC provides investment management and advisory services, focusing on fostering the development of innovative companies through active engagement and strategic guidance.
GE Capital
General Electric Company operates as a global infrastructure and technology firm, providing industrial and financial solutions across multiple sectors including healthcare and medical imaging.
What's next for Cerapedics?
Looking ahead, Cerapedics is well-positioned to leverage its recent capital influx to accelerate product commercialization and deepen its penetration into global healthcare markets. The company's strategic roadmap likely involves expanding the clinical applications of its P-15 peptide technology and strengthening its distribution networks to meet the rising demand for advanced bone graft substitutes.
As the orthopedic industry continues to prioritize minimally invasive and faster-healing solutions, Cerapedics remains focused on maintaining its competitive edge through rigorous research and development. The firm's ability to secure sustained investment from top-tier healthcare-focused venture firms and financial institutions provides the necessary runway to pursue long-term growth, potential strategic partnerships, and the continued evolution of its orthopedic portfolio.
